Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NousCom AG
This week's announcements include a new chairman at Horama and new CEOs at ISA Pharmaceuticals and Calidi Biotherapeutics, a new chief development officer at Protagonist Therapeutics, a new R&D head at Curis, and a new chief medical officer at Nouscom.
NousCom CEO and co-founder Alfredo Nicosia speaks to Scrip senior editor Lucie Ellis during BIO-Europe, a partnering meeting held in berlin Nov. 6-8, about the company's recent series B financing.
Semma's $114m Series B round and a $107m Series C for Arcus top November's list of biopharmaceutical venture capital deals. Forty Seven, Medeor and Tricida also closed sizeable rounds.
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule